IPCA Laboratories Limited has informed the Exchange regarding re-appointment of Mr Mr. Prashant Godha as Executive Director of the company w.e.f. August 16, 2026.
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ipca Laboratories reported strong FY2025-26 results with standalone revenue of Rs 7,337 Crores (up 10% YoY) and consolidated revenue of Rs 9,646 Crores (up 8% YoY). Consolidated profit after tax jumped 55% to Rs 1,141 Crores, with EPS at Rs 44.98. The Board recommended a dividend of Rs 6 per share (600%). Exceptional items included Rs 282 Crores in impairments related to subsidiaries and associates, partially offset by gains from asset sales. The Board also approved re-appointment of Mr. Prashant Godha as Executive Director for 5 years from August 2026; he is related to the Executive Chairman and Managing Director, indicating continued family management control. All financial results received unmodified audit opinion.
The strong profitability growth and dividend recommendation are positive signals for shareholders. The re-appointment of a promoter family member as Executive Director maintains continuity in leadership but also reinforces family control over the company.